Viewing Study NCT05428969

Home Icon Home Search Icon Search Certify Doc Icon Certify Doc Certify Doc Icon Genes Certify Doc Icon Clinical Trials Certify Doc Icon CompTox Processes Icon DrugMatrix Open Targets Icon Open Targets Processes Icon Products Support Icon Support Bugs Icon Bugs
Main Search Make This Study a Gene Therapy Make This Study a Not Gene Therapy Report Bug
Ignite Creation Date: 2025-12-24 @ 10:54 PM
Ignite Modification Date: 2026-05-03 @ 9:11 PM
Study NCT ID: NCT05428969
Status: ACTIVE_NOT_RECRUITING
Last Update Posted: 2025-12-01
First Post: 2022-06-15
Is NOT Gene Therapy: True
Has Adverse Events: False
Brief Title: A Study to Assess Safety, Tolerability and Preliminary Efficacy of Bexmarilimab in Combination With Standard of Care in Patients With Hematological Malignancies
Sponsor: Faron Pharmaceuticals Ltd
Organization:
Overview Dates Organization Conditions Design Enrollment Locations Outcomes Modules Raw JSON

Conditions & Keywords Data

Conditions:

Conditions

Condition Brief Condition Text View
None Acute Myeloid Leukemia View
None Chronic Myelomonocytic Leukemia View
None Myelodysplastic Syndromes View
None Relapsed/Refractory AML View
Keywords:

Keywords

Keyword Brief Keyword Text View
None Macrophages View
None Immunotherapy View
None Hematological View
None CLEVER-1 View
None bexmarilimab View
None hematological neoplasms View
None azacitidine View
None venetoclax View
None myeloid cells View